Postępy Dermatologii i Alergologii

Full text

3/2026 vol. 43
Review paper

Targeting macrophage function with botulinum toxin: a novel translational strategy for preventing and treating pathological scars

Ali Mohyeddin 1
,
Fazhi Qi 1

  1. Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai City, China

Adv Dermatol Allergol 2026; XLIII (3): 221–232

DOI: https://doi.org/10.5114/ada.2026.162707
Data publikacji online: 2026/07/19
Article file
PDIA Targeting.pdf
  1. Fang X, Wang Y, Chen H, et al. Hypertrophic scarring and keloids: Epidemiology, molecular pathogenesis, and therapeutic interventions. MedComm 2025; 6: e70381.
  2. Limandjaja GC, van Meijeren-Hoogendoorn RE, Louter JM, et al. Where two keloids meet: Invasive confluent growth of chest keloids, a case report. Burns Open 2024; 8: 92-3.
  3. Li X, Wang X, Shen T, et al. Advances in photodynamic therapy of pathologic scar. Photodiagnosis Photodyn Ther 2024; 46: 104040.
  4. Sheng M, Chen Y, Li H, et al. The application of corticosteroids for pathological scar prevention and treatment: current review and update. Burns Trauma 2023; 11: tkad009.
  5. AlBilasi TM, Alkublan RMK, Suayb AS, et al. Botulinum Toxin A for improving cosmetic outcomes in facial wound healing: a systematic review, meta-analysis, and dose-response evaluation. J Craniofac Surg 2026; 37: 31-8.
  6. Wang YX, Wang Y, Zhang Q, Zhang RD. Current research of botulinum toxin type A in prevention and treatment on pathological scars. Dermatol Surg 2023; 49: S34-40.
  7. Yao H, Jing SL, Huang KX, et al. Clinical features and mechanisms of differential wound healing and scarring across anatomical sites. Adv Wound Care 2025; DOI: 21621918251387627.
  8. Mahheidari N, Zamani S, Khademi R, et al. Biological macromolecules Alginate-Carboxymethyl Cellulose (Alg-CMC) hydrogel loaded with Botulinum toxin type A for skin wound treatment and functional tissue regeneration. Int J Biol Macromol 2025; 316: 144668.
  9. Huang C, Ogawa R. Role of inflammasomes in keloids and hypertrophic scars – lessons learned from chronic diabetic wounds and skin fibrosis. Int J Mol Sci 2022; 23: 6820.
  10. Yan L, Wang J, Cai X, et al. Macrophage plasticity: signaling pathways, tissue repair, and regeneration. MedComm 2024; 5: e658.
  11. Aitcheson SM, Frentiu FD, Hurn SE, et al. Skin wound healing: normal macrophage function and macrophage dysfunction in diabetic wounds. Molecules 2021; 26: 4917.
  12. Fernandez-Guarino M, Naharro-Rodriguez J, Bacci S. Aberrances of the wound healing process: a review. Cosmetics 2024; 11: 209.
  13. Downer M, Berry CE, Parker JB, et al. Current biomaterials for wound healing. Bioengineering 2023; 10: 1378.
  14. Jalalvand M, Khanmohammadi S, Akhtari M, et al. Macrophages in bone and synovial inflammation in rheumatoid arthritis. J Cell Immunol 2024; 5: 184-92.
  15. Nazari M, Taremi S, Elahi R, et al. Therapeutic properties of M2 macrophages in chronic wounds: an innovative area of biomaterial-assisted M2 macrophage targeted therapy. Stem Cell Rev Rep 2025; 21: 390-422.
  16. Feng P, Che Y, Gao C, et al. Profibrotic role of transcription factor SP1 in cross-talk between fibroblasts and M2 macrophages. Iscience 2023; 26: 108484.
  17. Georgakis MK, Bernhagen J, Heitman LH, et al. Targeting the CCL2–CCR2 axis for atheroprotection. Eur Heart J 2022; 43: 1799-808.
  18. Zheng ZF, Zhang JJ, Wu LF, et al. Inhibition of inducible nitric oxide synthase (iNOS) alleviates thoracic aortic aneurysm by regulating mitochondrial dynamics. Eur J Pharmacol 2025; 1005: 178071.
  19. Zhang J, Liu S, Ding W, et al. Resolution of inflammation, an active process to restore the immune microenvironment balance: a novel drug target for treating arterial hypertension. Ageing Res Rev 2024; 99: 102352.
  20. Abdelrahman AA, Bunch KL, Sandow PV, et al. Systemic administration of pegylated arginase-1 attenuates the progression of diabetic retinopathy. Cells 2022; 11: 2890.
  21. Sindrilaru A, Scharffetter-Kochanek K. Disclosure of the culprits: macrophages-versatile regulators of wound healing. Adv Wound Care 2013; 2: 357-68.
  22. Hong YK, Chang YH, Lin YC, et al. Inflammation in wound healing and pathological scarring. Adv Wound Care 2023; 12: 288-300.
  23. Seoudy WM, Mohy El Dien SM, Abdel Reheem TA, et al. Retracted: Macrophages of the M1 and M2 types play a role in keloids pathogenesis. Int Wound J 2023; 20: 38-45.
  24. Wei E, Hu M, Wu L, et al. TGF-b signaling regulates differentiation of MSCs in bone metabolism: disputes among viewpoints. Stem Cell Res Ther 2024; 15: 156.
  25. Han SS, Park I, Chang SE, et al. Augmented intelligence dermatology: deep neural networks empower medical professionals in diagnosing skin cancer and predicting treatment options for 134 skin disorders. J Investig Dermatol 2020; 140: 1753-61.
  26. Cai F, Wang P, Chen W, et al. The physiological phenomenon and regulation of macrophage polarization in diabetic wound. Mol Biol Rep 2023; 50: 9469-77.
  27. Xu X, Gu S, Huang X, et al. The role of macrophages in the formation of hypertrophic scars and keloids. Burns Trauma 2020; 8: tkaa006.
  28. Gregory KS, Newell AR, Mojanaga OO, et al. Crystal structures of the clostridium botulinum neurotoxin A6 cell binding domain alone and in complex with GD1a reveal significant conformational flexibility. Int J Mol Sci 2022; 23: 9620.
  29. Lin J, Wang X. Retracted: Effects of botulinum toxin type A in the prevention and treatment of facial hypertrophic scars: a meta-analysis. Int Wound J 2024; 21: e14796.
  30. Huang SH, Wu KW, Lo JJ, Wu SH. Synergic effect of botulinum toxin type A and triamcinolone alleviates scar pruritus by modulating epidermal hyperinnervation: a preliminary report. Aesth Surg J 2021; 41: NP1721-31.
  31. Korableva N, Romanenkov N, Kremlev D, et al. Prospects for use of botulinum toxin type a for prevention of hypertrophic and keloid scars after surgeries. Indian J Plastic Surg 2024; 57: 421-31.
  32. Sutedja EK, Sutedja E, Ruchiatan K, et al. Intralesional botulinum toxin A for keloid treatment: a review of efficacy, safety, and clinical applications. Clin Cosmet Investig Dermatol 2025; 18: 2103-17.
  33. Chang Y, Lee JWN, Holle AW. The mechanobiology of fibroblast activation in disease. APL Bioeng 2025; 9: 021505.
  34. Zou YP, Shan XF, Qiu JX, et al. Botulinum toxin type A inhibits M1 macrophage polarization by deactivation of JAK2/STAT1 and IkB/NFkB pathway and contributes to scar alleviation in aseptic skin wound healing. Biomed Pharmacother 2024; 174: 116468.
  35. Wang RH, Barbieri JS, Nguyen HP, et al. Clinical effectiveness and cost-effectiveness of teledermatology: Where are we now, and what are the barriers to adoption? J Am Acad Dermatol 2020; 83: 299-307.
  36. Kurtansky NR, D’Alessandro BM, Gillis MC, et al. The SLICE-3D dataset: 400,000 skin lesion image crops extracted from 3D TBP for skin cancer detection. Sci Data 2024; 11: 884.
  37. Berry CE, Downer Jr M, Morgan AG, et al. The effects of mechanical force on fibroblast behavior in cutaneous injury. Front Surg 2023; 10: 1167067.
  38. Bhatnagar T, Azim FT, Behrouzian M, et al. Assessing changes in range of motion in adolescent patients undergoing myoActivation® for chronic pain related to myofascial dysfunction: a feasibility study. Front Pain Res 2023; 4: 1225088.
  39. Ghaseminejad-Bandpey A, Etemadmoghadam S, Jabbari B. Botulinum toxin treatment of psoriasis – a comprehensive review. Toxins 2024; 16: 449.
  40. Dai X, Lei TC. Botulinum toxin A promotes the transdifferentiation of primary keloid myofibroblasts into adipocyte-like cells. Basic Clin Pharmacol Toxicol 2021; 129: 462-9.
  41. Trzpis M, Klaase J, Koop R, Broens P. Fissurectomy combined with botulinum toxin A: a review of short-and long-term efficacy of this treatment strategy for chronic anal fissure; a consecutive proposal of a treatment algorithm for chronic anal fissure. Coloproctology 2020; 42: 400-8.
  42. Maytharakcheep S, Bhidayasiri R. Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes. J Neural Transmission 2025; 132: 23-38.
  43. Chen S, Yang Y, Zhang D, et al. Local injection of botulinum toxin type A to prevent postoperative scar. J Craniofac Surg 2020; 31: 440-3.
  44. Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstruct Surg 2006; 117: 1758-66.
  45. Ali M, Xie B, Li P, et al. Botulinum toxin A prevents hypertrophic scarring by suppressing PARP14/SOCS2-mediated M2 polarization of macrophages. Biochim Biophys Acta Mol Cell Res 2025; 1872: 120003.
  46. Motamed S, Bakhshi R, Hedayatyanfard K, et al. Early post-operative use of Botulinum toxin type A in prevention of scar after mammoplasty and abdominoplasty. Australasian J Dermatol 2022; 63: 111-3.
  47. Bartkowska P, Roszak J, Ostrowski H, Komisarek O. Botulinum toxin type A as a novel method of preventing cleft lip scar hypertrophy – a literature review. J Cosmet Dermatol 2020; 19: 2188-93.
  48. Park GS, An MK, Yoon JH, et al. Botulinum toxin type A suppresses pro-fibrotic effects via the JNK signaling pathway in hypertrophic scar fibroblasts. Arch Dermatol Res 2019; 311: 807-14.
  49. Jiang A, Jiang R, Liu T. A meta-analysis of the efficacy and safety of botulinum toxin type A for the management of scars after facial surgery. J Cosmet Dermatol 2025; 24: e70111.
  50. Maini D. Botulinum neurotoxin type A as an adjuvant to reduce scarring after dermatological surgery. J Drugs Dermatol 2021; 20: 677-80.
  51. Gao Y, Li W, Li Z, et al. Clinical efficacy analysis of botulinum toxin type A combined with superficial radiotherapy after chest keloid surgery. Aesth Plast Surg 2025; 49: 6333-8.
  52. Han MW, Park JU. Treatment of a lip defect in a patient with chorea-acanthocytosis using a combination of surgical and adjuvant onabotulinumtoxinA therapy: a case report. Arch Craniofac Surg 2024; 25: 257-61.
  53. Zhang Y, Zhang S. Clinical application and mechanism of botulinum toxin type A in scar treatment. Zhonghua Shao Shang Za Zhi 2021; 37: 705-10.
  54. Tosa M, Ogawa R. Photodynamic therapy for keloids and hypertrophic scars: a review. Scars Burns Healing 2020; 6: 2059513120932059.
  55. Feng F, Liu M, Pan L, et al. Biomechanical regulatory factors and therapeutic targets in keloid fibrosis. Front Pharmacol 2022; 13: 906212.
  56. Chandar V, Goykadosh BM, Parameswaran H. Intercellular contact is sufficient to drive fibroblast to myofibroblast transitions. arXiv preprint arXiv 2025; 2503.01834.
  57. Ezzo M, Hinz B. Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases. Pharmacol Ther 2023; 250: 108528.
  58. Wei YH, Liao SL, Wang SH, et al. Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of Graves’ ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Front Endocrinol 2021; 11: 607968.
  59. Chang YC, Wu JW, Wang CW, Jang ACC. Hippo signaling-mediated mechanotransduction in cell movement and cancer metastasis. Front Mol Biosci 2020; 6: 157.
  60. Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 2020; 19: 480-94.
  61. Abedini R, Mehdizade Rayeni N, Haddady Abianeh S, et al. Botulinum toxin type A injection for mammoplasty and abdominoplasty scar management: a split-scar double-blinded randomized controlled study. Aesth Plast Surg 2020; 44: 2270-2276.
  62. Khatery BH, Hussein HA, Abd-el-Raheem TA, et al. Assessment of intralesional injection of botulinum toxin type A in hypertrophic scars and keloids: clinical and pathological study. Dermatol Ther 2022; 35: e15748.
  63. Wang S, Yan H, Fang B, et al. A myogenic niche with a proper mechanical stress environment improves abdominal wall muscle repair by modulating immunity and preventing fibrosis. Biomaterials 2022; 285: 121519.
  64. Elshahed AR, Elmanzalawy KS, Shehata H, ElSaie ML. Effect of botulinum toxin type a for treating hypertrophic scars: a split-scar, double-blind randomized controlled trial. J Cosmet Dermatol 2020; 19: 2252-8.
  65. Las Heras K, Garcia-Orue I, Rancan F, et al. Modulating the immune system towards a functional chronic wound healing: a biomaterials and nanomedicine perspective. Adv Drug Deliv Rev 2024; 210: 115342.
  66. Zhang Y, Wang G. Research progress of botulinum toxin type A in the treatment of chronic rhinitis. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 36: 878-83.
  67. Yeh TC, Chen PC, Su YR, Kuo HC. Effect of botulinum toxin A on bladder pain – molecular evidence and animal studies. Toxins 2020; 12: 98.
  68. Bonadio JD, Bashiri G, Halligan P, et al. Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications. Adv Drug Deliv Rev 2024; 209: 115303.
  69. Zhang H, Wang M, Zhao X, et al. Role of stress in skin diseases: a neuroendocrine-immune interaction view. Brain Behav Immun 2024; 116: 286-302.
  70. Ud-Din S, Bayat A. Controlling inflammation pre-emptively or at the time of cutaneous injury optimises outcome of skin scarring. Front Immunol 2022; 13: 883239.
  71. Zhang K, Ren Y, Lv J, et al. Exploring the biomarkers and potential mechanisms of botulinum toxin type A in the treatment of microglial inflammatory activation through P2X7 receptors based on transcriptome sequencing. Curr Pharm Design 2024; 30: 3038-53.
  72. Wang X, Tian S, Wang H, et al. Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2/MyD88 and SNAP23. Cell Biosci 2020; 10: 141.
  73. Lan YJ, Yan RS, Lei ZY, Fan D. The effects of botulinum toxin type A on the biological behavior of fibroblasts on silicone implants. Aesth Plast Surg 2024; 48: 5358-66.
  74. Cao Y, Sun J, Qin S, et al. Advances and challenges in immune-modulatory biomaterials for wound healing applications. Pharmaceutics 2024; 16: 990.
  75. Falduto GH, Pfeiffer A, Luker A, et al. Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications. Pharmacol Ther 2021; 220: 107718.
  76. Krzyszczyk P, Schloss R, Palmer A, Berthiaume F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. Front Physiol 2018; 9: 419.
  77. Xiong J, Xiao R, Zhao J, et al. Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy. J Transl Med 2024; 22: 85.
  78. Wilson HM. Modulation of macrophages by biophysical cues in health and beyond. Discov Immunol 2023; 2: kyad013.
  79. Wang K, Wen D, Xu X, et al. Extracellular matrix stiffness – the central cue for skin fibrosis. Front Mol Biosci 2023; 10: 1132353.
  80. Guan Y, Zhang M, Song J, et al. CaMKK2 regulates macrophage polarization induced by matrix stiffness: implications for shaping the immune response in stiffened tissues. Adv Sci 2025; 12: 2417778.
  81. Tschumperlin DJ, Lagares D. Mechano-therapeutics: targeting mechanical signaling in fibrosis and tumor stroma. Pharmacol Ther 2020; 212: 107575.
  82. Qian Y, Wei W, Pan T, et al. Comparison research on the therapeutic effects of botulinum toxin type A and stromal vascular fraction gel on hypertrophic scars in the rabbit ear model. Burns 2024; 50: 178-89.
  83. Byun HJ, Park JH, Lee JH. Combination treatment of intra/perilesional botulinum toxin-a injection and ablative fractional laser for better clinical outcomes of hypertrophic fibrotic thyroidectomy scars following fractional ablative laser resurfacing. Ann Dermatol 2021; 33: 170.
  84. Atcha H, Meli VS, Davis CT, et al. Crosstalk between CD11b and Piezo1 mediates macrophage responses to mechanical cues. Front Immunol 2021; 12: 689397.
  85. He J, Shan S, Jiang T, et al. Mechanical stretch preconditioned adipose-derived stem cells elicit polarization of anti-inflammatory M2-like macrophages and improve chronic wound healing. FASEB J 2024; 38: e23626.
  86. Sousa AB, Águas AP, Barbosa MA, Barbosa JN. Immunomodulatory biomaterial-based wound dressings advance the healing of chronic wounds via regulating macrophage behavior. Regen Biomaterials 2022; 9: rbac065.
  87. Atcha H, Jairaman A, Holt JR, et al. Mechanically activated ion channel Piezo1 modulates macrophage polarization and stiffness sensing. Nat Commun 2021; 12: 3256.
  88. Xu Y, Huang Y, Cheng X, et al. Mechanotransductive receptor Piezo1 as a promising target in the treatment of fibrosis diseases. Front Mol Biosci 2023; 10: 1270979.
  89. Li R, Feng D, Han S, et al. Macrophages and fibroblasts in foreign body reactions: how mechanical cues drive cell functions? Materials Today Bio 2023; 22: 100783.
  90. Mittelheisser V, Gensbittel V, Bonati L, et al. Evidence and therapeutic implications of biomechanically regulated immunosurveillance in cancer and other diseases. Nat Nanotechnol 2024; 19: 281-97.
  91. He T, Xiao Y, Guo Z, et al. Modulation of macrophage function by bioactive wound dressings with an emphasis on extracellular matrix-based scaffolds and nanofibrous composites. Pharmaceutics 2023; 15: 794.
  92. Duan Y, Zhang K, Xu Y, et al. A promising method for reducing the incidence of diabetic foot ulcers: regulating foot temperature during walking. Med Hypoth 2024; 183: 111268.
  93. Pozo-Rosich P, Alpuente A, Silberstein SD, Burstein R. Insights from 25 years of onabotulinumtoxinA in migraine – mechanisms and management. Nat Rev Neurol 2024; 20: 555-68.
  94. Fan Y, Guo X, Tian Y, et al. Botulinum toxin type A inhibits the formation of hypertrophic scar through the JAK2/STAT3 pathway. Biomol Biomed 2024; 25: 249.
  95. Yang Y, Zhao M, Kuang Q, et al. A comprehensive review of phytochemicals targeting macrophages for the regulation of colorectal cancer progression. Phytomedicine 2024; 128: 155451.
  96. Ambrin G, Kang YJ, Van Do K, et al. Botulinum neurotoxin induces neurotoxic microglia mediated by exogenous inflammatory responses. Adv Sci 2024; 11: 2305326.
  97. Masuyer G, Davies JR, Stenmark P. Mechanism of ganglioside receptor recognition by botulinum neurotoxin serotype E. Int J Mol Sci 2021; 22: 8315.
  98. Alkafaas SS, Abdallah AM, Hassan MH, et al. Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS-CoV-2 infectivity. BMC Public Health 2024; 24: 395.
  99. Wu PP, Cao BR, Tian FY, Gao ZB. Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil. Neurosci Bull 2024; 40: 594-608.
  100. Valois LS, Wilkinson KA, Nakamura Y, Henley JM. Endocytosis, trafficking and exocytosis of intact full-length botulinum neurotoxin type a in cultured rat neurons. Neurotoxicology 2020; 78: 80-7.
  101. Sun Y, Sha Y, Cui G, et al. Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy. Adv Drug Deliv Rev 2023; 192: 114624.
  102. Pozzi D, Corradini I, Matteoli M. The control of neuronal calcium homeostasis by SNAP-25 and its impact on neurotransmitter release. Neuroscience 2019; 420: 72-8.
  103. Matsunaga H, Halder SK, Ueda H. Involvement of SNARE protein interaction for non-classical release of DAMPs/alarmins proteins, prothymosin alpha and S100A13. Cell Mol Neurobiol 2021; 41: 1817-28.
  104. Helaine S, Conlon BP, Davis KM, Russell DG. Host stress drives tolerance and persistence: the bane of anti-microbial therapeutics. Cell Host Microbe 2024; 32: 852-62.
  105. Matak I, Lackoviæ Z. Botulinum neurotoxin type A: actions beyond SNAP-25? Toxicology 2015; 33: 579-84.
  106. Leslie J, Macia MG, Luli S, et al. c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis. Nat Metab 2020; 2: 1350-67.
  107. Lazar M, Sandulescu M, Barbu EC, et al. The role of cytokines and molecular pathways in lung fibrosis following SARS-CoV-2 infection: a physiopathologic (re)view. Biomedicines 2024; 12: 639.
  108. Chu X, Xiong Y, Knoedler S, et al. Immunomodulatory nanosystems: advanced delivery tools for treating chronic wounds. Research 2023; 6: 0198.
  109. Naidu G, Tripathi DK, Nagar N, et al. Targeting chemokine-receptor mediated molecular signaling by ethnopharmacological approaches. J Ethnopharmacol 2024; 325: 117837.
  110. Ge Y, Huang M, Yao YM. Efferocytosis and its role in inflammatory disorders. Front Cell Develop Biol 2022; 10: 839248.
  111. Sukka SR, Ampomah PB, Darville LN, et al. Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution. Nat Metabol 2024; 6: 1736-55.
  112. Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev 2024; 207: 115239.
  113. Tang PMK, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol 2019; 15: 144-58.
  114. Yin J, Zhang S, Yang C, et al. Mechanotransduction in skin wound healing and scar formation: Potential therapeutic targets for controlling hypertrophic scarring. Front Immunol 2022; 13: 1028410.
  115. Wang J, Huang L, Li J, et al. Efficacy and safety of sequential treatment with botulinum toxin type A, fractional CO2 laser, and topical growth factor for hypertrophic scar management: a retrospective analysis. Sci Rep 2024; 14: 27233.
  116. Shoval H, Levin J, Friel K, Kim H. Safety of combined salivary gland and multilevel intramuscular onabotulinumtoxinA injections with and without ethanol in pediatric patients with cerebral palsy: a retrospective study. J Pediatr Rehab Med 2019; 12: 189-96.
  117. Wang W, Kong M, Dou Y, et al. Selective expression of a SNARE-cleaving protease in peripheral sensory neurons attenuates pain-related gene transcription and neuropeptide release. Int J Mol Sci 2021; 22: 8826.
  118. Zhang S, Li K, Yu Z, et al. Dramatic effect of botulinum toxin type A on hypertrophic scar: a promising therapeutic drug and its mechanism through the SP-NK1R pathway in cutaneous neurogenic inflammation. Front Med 2022; 9: 820817.
  119. Wen D, Gao Y, Ho C, et al. Focusing on mechanoregulation axis in fibrosis: sensing, transduction and effecting. Front Mol Biosci 2022; 9: 804680.
  120. Yu J, Nam D, Park KS. Substance P enhances cellular migration and inhibits senescence in human dermal fibroblasts under hyperglycemic conditions. Biochem Biophys Res Commun 2020; 522: 917-23.
  121. Chen M, Zhang Y, Zhou P, et al. Substrate stiffness modulates bone marrow-derived macrophage polarization through NF-kB signaling pathway. Bioactive Materials 2020; 5: 880-90.
  122. Arpinati L, Carradori G, Scherz-Shouval R. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer 2024; 24: 676-93.
  123. Sun T, Zhou C, Lu F, et al. Adipose-derived stem cells in immune-related skin disease: a review of current research and underlying mechanisms. Stem Cell Res Ther 2024; 15: 37.
  124. Qiang P, Hao J, Yang F, et al. Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-b1 pathway in mice induced with aldosterone. Front Immunol 2022; 13: 948658.
  125. Wu H, Yu Y, Huang H, et al. Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem cells. Cell 2020; 180: 107-21. e117.
  126. Rabas N, Ferreira RM, Di Blasio S, Malanchi I. Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells. Nat Rev Cancer 2024; 24: 829-49.
  127. Chen H, Huang Z, Sun B, et al. Evaluating research waste and traits among randomized controlled trials of scars over the past 20 years: a cross-sectional study. Postgrad Med J 2024; 100: 925-31.
  128. Guo X, Song G, Zhang D, Jin X. Efficacy of botulinum toxin type A in improving scar quality and wound healing: a systematic review and meta-analysis of randomized controlled trials. Aesth Surg J 2020; 40: NP273-85.
  129. Jetten N, Roumans N, Gijbels MJ, et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PLoS One 2014; 9: e102994.
  130. Wilgus TA. Inflammation as an orchestrator of cutaneous scar formation: a review of the literature. Plastic Aesth Res 2020; 7: 54.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications